These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29076005)

  • 1. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
    Nakamae H; Fukuda T; Nakaseko C; Kanda Y; Ohmine K; Ono T; Matsumura I; Matsuda A; Aoki M; Ito K; Shibayama H
    Int J Hematol; 2018 Mar; 107(3):327-336. PubMed ID: 29076005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial.
    Nakamae H; Yamamoto M; Sakaida E; Kanda Y; Ohmine K; Ono T; Matsumura I; Ishikawa M; Aoki M; Maki A; Shibayama H
    Int J Hematol; 2022 Jan; 115(1):33-42. PubMed ID: 34508295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
    Hochhaus A; Saglio G; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre PD; Etienne G; Dorlhiac-Llacer PE; Clark RE; Flinn IW; Nakamae H; Donohue B; Deng W; Dalal D; Menssen HD; Kantarjian HM
    Leukemia; 2016 May; 30(5):1044-54. PubMed ID: 26837842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
    Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
    Nakamae H; Shibayama H; Kurokawa M; Fukuda T; Nakaseko C; Kanda Y; Nagai T; Ohnishi K; Maeda Y; Matsuda A; Amagasaki T; Yanada M
    Int J Hematol; 2011 May; 93(5):624-632. PubMed ID: 21523338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
    Larson RA; Hochhaus A; Hughes TP; Clark RE; Etienne G; Kim DW; Flinn IW; Kurokawa M; Moiraghi B; Yu R; Blakesley RE; Gallagher NJ; Saglio G; Kantarjian HM
    Leukemia; 2012 Oct; 26(10):2197-203. PubMed ID: 22699418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
    Wang J; Shen ZX; Saglio G; Jin J; Huang H; Hu Y; Du X; Li J; Meng F; Zhu H; Hu J; Wang J; Hou M; Hertle S; Menssen HD; Ortmann CE; Tribouley C; Yuan Y; Baccarani M; Huang X
    Blood; 2015 Apr; 125(18):2771-8. PubMed ID: 25766724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
    Kantarjian HM; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Boquimpani C; Pasquini R; Clark RE; Dubruille V; Flinn IW; Kyrcz-Krzemien S; Medras E; Zanichelli M; Bendit I; Cacciatore S; Titorenko K; Aimone P; Saglio G; Hochhaus A
    Leukemia; 2021 Feb; 35(2):440-453. PubMed ID: 33414482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.
    Garnock-Jones KP
    Drugs; 2011 Aug; 71(12):1579-90. PubMed ID: 21861543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
    Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
    Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
    Erba HP; Pham DC; Zaiden R; Vu H; Tai S
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
    Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
    Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
    Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
    Giles FJ; Rosti G; Beris P; Clark RE; le Coutre P; Mahon FX; Steegmann JL; Valent P; Saglio G
    Expert Rev Hematol; 2010 Dec; 3(6):665-73. PubMed ID: 21091142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
    Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
    Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase].
    Yin H; Chen LF; Cui JK; Xiong YY; You Y; Zou P; Li WM
    Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):810-815. PubMed ID: 29136709
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
    Gugliotta G; Castagnetti F; Breccia M; Levato L; D'Adda M; Stagno F; Tiribelli M; Salvucci M; Fava C; Martino B; Cedrone M; Bocchia M; Trabacchi E; Cavazzini F; Usala E; Russo Rossi A; Bochicchio MT; Soverini S; Alimena G; Cavo M; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G;
    Haematologica; 2015 Sep; 100(9):1146-50. PubMed ID: 26113419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.